Functional characterization of human natural killer cells responding to Mycobacterium bovis bacille Calmette-Guérin

The kinetics of activation and induction of several effector functions of human natural killer (NK) cells in response to Mycobacterium bovis bacille Calmette-Guérin (BCG) were investigated. Owing to the central role of monocytes/macrophages (MM) in the initiation and maintenance of the immune response to pathogens, two different experimental culture conditions were analysed. In the first, monocyte-depleted nylon wool non-adherent (NW) cells from healthy donors were stimulated with autologous MM preinfected with BCG (intracellular BCG). In the second, the NW cells were directly incubated with BCG, which was therefore extracellular. In the presence of MM, CD4+ T lymphocytes were the cell subset mainly expressing the activation marker, CD25, and proliferating with a peak after 7 days of culture. In contrast, in response to extracellular BCG, the peak of the proliferative response was observed after 6 days of stimulation, and CD56+ CD3- cells (NK cells) were the cell subset preferentially involved. Such proliferation of NK cells did not require a prior sensitization to mycobacterial antigens, and appeared to be dependent upon contact between cell populations and bacteria. Following stimulation with extracellular BCG, the majority of interferon-gamma (IFN-gamma)-producing cells were NK cells, with a peak IFN-gamma production at 24-30 hr. Interleukin (IL)-2 and IL-4 were not detectable in NK cells or in CD3+ T lymphocytes at any time tested. IL-12 was not detectable in the culture supernatant of NW cells stimulated with extracellular BCG. Compared to the non-stimulated NW cells, the NW cells incubated for 16-20 hr with BCG induced the highest levels of expression of apoptotic/death marker on the NK-sensitive K562 cell line. BCG also induced expression of the activation marker, CD25, and proliferation, IFN-gamma production and cytotoxic activity, on negatively selected CD56+ CD3- cells. Altogether, the results of this study demonstrate that extracellular mycobacteria activate several NK-cell functions and suggest a possible alternative mechanism of NK-cell activation as the first line of defence against mycobacterial infections.     

卡介苗对豚鼠实验性哮喘的预防性治疗作用

目的:观察卡介苗(BCG)对哮喘豚鼠的预防治疗作用。方法:采用31只豚鼠,分为3组进行处理,分别为对照组、卵蛋白(OVA)致敏组和BCG处理组。用OVA(Ⅲ级)致敏豚鼠复制豚鼠哮喘模型。结果:本模型采用10%的OVA致敏,1%的OVA激发,所有动物都表现有不同程度的过敏反应症状。实验动物在接受BCG注射后,表现为以下特点:一是外周血淋巴细胞和单核细胞增加;二是BALF中细胞分类的变化,支气管肺泡灌洗液(BALF)中以淋巴细胞的增加最为明显。 经过OVA致敏的动物BALF和肺组织中嗜酸性粒细胞(EOS)明显增加,BCG不同程度地降低肺组织EOS的气道浸润及减轻OVA致敏豚鼠的气道反应。结论:[HTSS]使用本实验体系BCG可以减轻实验性哮喘的气道炎症反应。     

An enzyme-linked immunosorbent assay (ELISA) for the measurement of antibodies to different parts of the gram-negative lipopolysaccharide core region

Bovine serum albumin was complexed with the core antigens of either Escherichia coli J5 LPS, Salmonella minnesota R595 LPS or E. coli lipid A. These core-BSA complexes were used for solid-phase coating in ELISAs for anti-core antibodies. Antibodies, binding to various parts of the core region were easily quantified in a single experimental set-up, which was hitherto not possible. The ELISA has only 3 incubation steps and is not costly as only moderate amounts of the core antigens (i.e., 1 microgram per test) were needed for coating. The sensitivity proved to be excellent and the complexes were biologically fully active (compared to native, smooth LPS), which make them suitable for the screening (after fusion) of monoclonal anti-core antibodies. Another possible application is the large-scale screening of blood-bank sera in order to find samples with a high anti-core antibody content.     

重组卡介苗及猪苓多糖对荷瘤小鼠巨噬细胞NO释放量的影响

目的 观察重组卡介苗（rBCG)和中药猪苓多糖（PPS），对荷瘤小鼠空巨噬细胞释放NO的影响。方法 将黑色素瘤细胞株B16接种于小鼠左大腿外侧皮下，建立荷瘤小鼠模型，分别用rBCG－IL-2,rBCG-IL-2 PPSPPS进行局部治疗。于给药后第1，2，3和5wk处死小鼠，用NO酶法测定小鼠腹腔巨噬细胞释放NO的水平，并观察不同实验组瘤体的变化。结果 rBCG－IL－2组小鼠腹腔巨噬细胞释放NO的水平最高。与对照组相比较，PPS组小鼠腹腔巨噬细胞释放NO的水平在第1wk与第2wk增高，第3wk起与对照组释放的NO水平没有差异。rBCG－IL－2组小鼠随给药时间的延长，皮下瘤体逐渐缩小。PPS组小鼠瘤体在给药后第1wk和第2wk生长缓慢，第3wk起瘤体生长速度明显增加。结论 rBCG－IL－2与PPS能提高小鼠腹腔巨噬细胞释放NO的水平，rBCG－IL－2能明显抑制肿瘤生长。     

Cytotoxic action of macrophages activated by BCG on tumor target cellsin vitro

The activating action of liquid BCG vaccine, lyophilized BCG vaccine, and killed BCG cells on macrophages was studied. Activation of mouse peritoneal macrophages was identified by their cytotoxic actionin vitro on syngeneic tumor target cells labeled with⁵¹Cr. Macrophages obtained from mice two to three weeks after a single injection of liquid BCG vaccine were shown to have a cytotoxic action on tumor cells. A single injection of lyophilized BCG vaccine or killed BCG cells into mice did not cause activation of their macrophages. Two injections of liquid or lyophilized BCG vaccine caused activation of macrophages much earlier — three to five days after the second injection. Intraperitoneal injection of BCG activated macrophages to a greater degree than subcutaneous injection.Laboratory of Experimental Tumor Therapy, P. A. Gertsen Moscow Oncologic Research Institute. (Presented by Academician of the Academy of Medical Sciences of the USSR A. D. Timofeevskii.) Translated from Byulleten' Éksperimental'noi Biologii i Meditsiny, Vol. 87, No. 1, pp. 36–39, January, 1979.     

Biochemical characterization of I-Ak proteins from mutant antigen-presenting B-cell--B-lymphoma hybridomas

Chemically induced mutants of an I-Ak,d expressing antigen-presenting B-cell--B-lymphoma hybridoma have recently been generated by immunoselection in vitro and were found to possess alterations in some of their serologically and functionally defined I-Ak region dependent functions. In order to identify at the structural level the origin of the differences in serological and functional properties of these mutants, I-Ak molecules from several of these mutant hybridomas were compared biochemically to wild-type I-Ak polypeptides by two-dimensional gel electrophoresis and high-pressure liquid chromatographic tryptic peptide analyses. Two-dimensional gel electrophoresis indicated that no major structural alterations, resulting in changes in mol. wt or charge, had occurred in the Ak alpha or Ak beta polypeptides from the mutant cells. Likewise, Ak alpha peptide maps of the mutants were indistinguishable from the normal Ak alpha peptide maps. However, two of the three mutants studied did exhibit one additional peptide in their Ak beta peptide maps. These results suggest that the major deficiencies in T-cell-activating functions of these mutants are a result of a limited alteration in the Ak beta polypeptide primary structure.     

探讨BCG初次免疫结核杆菌DNA疫苗加强免疫方案的效应

目的:探讨BCG初次免疫(BCG-prime),结核杆菌共表达DNA疫苗加强免疫(DNA疫苗-boost)的策略对小鼠的免疫效果。方法:将BCG及结核杆菌重组DNA疫苗依次免疫小鼠,通过检测CTL和NK细胞的杀伤活性和特异性淋巴细胞增殖,以及小鼠血清抗体及细胞因子的水平,观测BCG-prime、共表达结核杆菌Ag85A/GM-CSFDNA疫苗boost策略对小鼠的免疫效果。结果:采用prime-boost免疫策略组的小鼠CTL的杀伤活性明显增强、特异性淋巴细胞明显增殖、IFN-γ的水平明显增高,NK细胞杀伤活性与对照组相比也有一定提高,但未超过BCG单独免疫效果。免疫小鼠血清特异性抗体的滴度超过单独DNA疫苗免疫组。结论:在采用BCG-prime-结核杆菌DNA疫苗boost免疫策略后,能增强对小鼠的免疫效应,尤其是Th1型细胞免疫反应增强明显,为进一步在动物体内进行保护性效应试验的研究提供了实验依据。     

卡介苗多糖核酸对支气管哮喘合并鼻炎患儿治疗的研究

目的 探讨卡介苗多糖核酸(BCG-PSN)对支气管哮喘合并鼻炎患儿Th1/Th2功能及肺通气功能的影响.方法 37例哮喘患儿随机分为治疗组和对照组两组.按照分级治疗的标准给与相应的糖皮质激素吸入治疗,治疗组加用BCG-PSN,随访6个月,比较治疗前和治疗后血清IFN-γ、IL-4的浓度及IFN-γ/IL-4比值、血浆总IgE、肺功能、鼻炎积分、哮喘发作需急诊就诊的次数、呼吸道感染的次数.结果治疗后治疗组,IL-4、IgE明显下降,IFN-γ及IFN-γ/IL-4比值明显升高;差异有统计学意义(P＜0.05),而对照组无明显改变,差异无统计学意义(P＜0.05).两组肺功能均明显改善,差异有统计学意义(P＜0.05).治疗组哮喘发作需急诊就诊的次数为(0.81±0.20)次,对照组为(1.72±0.80)次,差异有统计学意义,(t=4.15,P＜0.05);治疗组呼吸道感染(1.15±0.55)次,对照组(3.21±0.73)次,差异有统计学意义,(t=3.98,P＜0.05);治疗组鼻炎发作(1.31±0.42)次、对照组(1.11±0.39)次,差异无统计学意义,(t=2.31,P＜0.05).结论 BCG-PSN具有纠正Th1/Th2失衡,减轻气道炎症,改善肺通气功能,提高免疫力的作用.对于哮喘合并过敏性鼻炎的患儿,除针对气道慢性炎症使用糖皮质激素进行抗炎治疗外,同时应重视免疫调节治疗.     

Prostaglandin E2 down-regulates viable Bacille Calmette-Guérin-induced macrophage cytotoxicity against murine bladder cancer cell MBT-2 in vitro

The regulatory effect of prostaglandin (PG) E2 and a cyclooxygenase (COX) inhibitor on Bacille Calmette-Guérin (BCG)-induced macrophage cytotoxicity in a bladder cancer cell, MBT-2, was studied in vitro. BCG stimulated thioglycollate-elicited murine peritoneal exudate cells (PEC) to induce cytotoxic activity and to produce cytokines such as interferon (IFN)-gamma, tumour necrosis factor (TNF)-alpha and PGE2. NS398, a specific COX-2 inhibitor, and indomethacin (IM), a COX-1 and COX-2 inhibitor, enhanced viable BCG-induced cytotoxic activity and IFN-gamma and TNF-alpha production of PEC. However, NS398 and IM did not enhance these activities induced by killed BCG. Enhanced cytotoxicity was mediated by increased amounts of IFN-gamma and TNF-alpha. Exogenous PGE2 reduced cytotoxic activity and IFN-gamma and TNF-alpha production of PEC. These results suggest that PGE2 produced by BCG-activated macrophages has a negative regulatory effect on the cytotoxic activity of macrophages. Accordingly, a PG synthesis inhibitor may be a useful agent to enhance BCG-induced antitumour activity of macrophages.